MedTrace Logo

A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection

NCT02453789 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-04-19

No results posted yet for this study

Summary

The purpose of the study is to assess the efficacy of Alginate oligosaccharide (OligoG) dry powder for inhalation in cystic fibrosis (CF) patients with a Burkholderia spp. infection.

Conditions

Interventions

DRUG

Alginate oligosaccharide

Inhalation of dry powder for inhalation (DPI)

DRUG

Placebo

Sponsors & Collaborators

  • AlgiPharma AS

    lead INDUSTRY

Principal Investigators

  • Rainald Fischer, MD, PD · Pneumologische Praxis Pasing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-03-31
Completion
2017-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453789 on ClinicalTrials.gov